Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 27Premenopausal Breast Cancer 2Breast Neoplasms, Male 2Sexual Dysfunctions, Psychological 1Patient Compliance 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Breast Cancer Invasive 1

Interventions

Trastuzumab 33pertuzumab 18Docetaxel 16pyrotinib 15Paclitaxel 7Capecitabine 6tucatinib 5Carboplatin 5Ado-Trastuzumab Emtansine 4trastuzumab deruxtecan 3neratinib 3atezolizumab 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2pegfilgrastim 1palbociclib 1margetuximab 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Hospital Information Systems 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Leuprolide × Breast × Clear all
NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Fudan University

Phase 2 Not yet recruiting
288 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡